Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312767 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL708581 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16710007 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1312765 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL708582 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL693616 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1311851 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23794778 | 0.89 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL30718547 | 0.89 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23794776 | 0.89 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0336230-B1 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-02-12 | — | — | EP | disclosed |
| US-5436140-A | Cyclic peptides as antagonist, analgesics or antihistamines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| US-5217952-A | Analgesics, antihistamine | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
| US-4775670-A | BACTERICIDES, ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0048953-B1 | BETA-LACTAM ANTIBIOTICS | E.R. Squibb & Sons, Inc. (US) | 1988-03-09 | — | — | EP | disclosed |
| EP-0187355-A1 | Process for preparing beta-lactam antibiotics | E.R. Squibb & Sons, Inc. (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4551276-A | 2-Oxoazetidin-1-yloxymethyl sulfonic acid and analogs | E. R. SQUIBB & SONS, INC. (US) | 1985-11-05 | — | — | US | disclosed |
| US-4529698-A | Culturing Chromobacterium | E. R. SQUIBB & SONS, INC. (US) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CTSK 3925/4885CTSS 3911/4885CA1 3605/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | CTSK 1667/4885CTSS 1732/4885CA1 1660/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | CTSK 619/4885CTSS 738/4885CA1 4539/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | CTSK 881/4885CTSS 1875/4885CA1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.